Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024
Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organicQ2 GAAP and.
KORU Medical Systems, Inc. , a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion.
01.05.2024 - KORU Medical Systems, Inc. (NASDAQ: KRMD) ( KORU Medical or the Company ), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion .
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.